Sanofi (SNY) has halted studies of its Fedratinib treatment for rare bone-marrow cancers, due to safety concerns. The move follows reports of trial patients displaying symptoms associated with the neurological disorder Wernicke's encephalopathy ...
Sanofi SA (ADR) (NYSE:SNY) gained 0.76%, trading on 3.08 million shares, to end the trade at $52.99. The stock changed hands in a range of $52.61 to $53.05, bringing its market capitalization to about $141.18 billion.
US Food and Drug Administration staff has said Sanofi SA (ADR) (NYSE:SNY)'s drug Lemtrada, which is develop for treatment of multiple sclerosis, may not provide sufficient benefit to patients to overshadow possibilities of cancer.
After months of muted progress JAK inhibitors and myelofibrosis are hotting up again just in time for next month's American Society of Hematology meeting, although the days when the space was the subject of frenetic deal activity are probably behind it.